Alzheimer's disease biomarkers detection in human samples by efficient capturing through porous magnetic microspheres and labelling with electrocatalytic gold nanoparticles

0441435 - ÚMCH 2015 RIV NL eng J - Článek v odborném periodiku
de la Escosura-Muniz, A. - Plichta, Zdeněk - Horák, Daniel - Merkoci, A.
Alzheimer's disease biomarkers detection in human samples by efficient capturing through porous magnetic microspheres and labelling with electrocatalytic gold nanoparticles.
Biosensors and Bioelectronics. Roč. 67, 15 May (2015), s. 162-169. ISSN 0956-5663. E-ISSN 1873-4235
Grant CEP: GA MŠMT 7E12053
GRANT EU: European Commission(XE) 246513 - NADINE
Institucionální podpora: RVO:61389013
Klíčová slova: porous magnetic microspheres * gold nanoparticles * electrochemical immunoassay
Kód oboru RIV: CD - Makromolekulární chemie
Impakt faktor: 7.476, rok: 2015

A nanobiosensor based on the use of porous magnetic microspheres (PMM) as efficient capturing/pre-concentrating platform is presented for detection of Alzheimer′s disease (AD) biomarkers. These PMMs prepared by a multistep swelling polymerization combined with iron oxide precipitation afford carboxyl functional groups suitable for immobilization of antibodies on the particle surface allowing an enhanced efficiency in the capturing of AD biomarkers from human serum samples. The AD biomarkers signaling is produced by gold nanoparticle (AuNP) tags monitored through their electrocatalytic effect towards hydrogen evolution reaction (HER). Novel properties of PMMs in terms of high functionality and high active area available for enhanced catalytic activity of the captured AuNPs electrocatalytic tags are exploited for the first time. A thorough characterization by scanning transmission electron microscope in high angle annular dark field mode (STEM-HAADF) demonstrates the enhanced ability of PMMs to capture a higher quantity of analyte and consequently of electrocatalytic label, when compared with commercially available microspheres. The optimized and characterized PMMs are also applied for the first time for the detection of beta amyloid and ApoE at clinical relevant levels in cerebrospinal fluid (CSF), serum and plasma samples of patients suffering from AD.
Trvalý link: http://hdl.handle.net/11104/0245261